

## WEST Search History

DATE: Thursday, April 17, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L11	6486303	2	L11
L10	6534300	1	L10
L9	6537785	1	L9
L8	L7 and l6	15	L8
L7	moore.xa.	1540	L7
L6	furin	536	L6
L5	L4 with furin	4	L5
L4	L2 with subunit	51	L4
L3	L2 and subunit	4278	L3
L2	FUSION WITH CLEAVS	7800	L2
L1	SUBUNIT WITH FURIN	15	L1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1800exs

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*

SESSION RESUMED IN FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIODBASE, BIOTECHNO, WPIDS' AT 16:37:04 ON 17 APR 2003

FILE 'MEDLINE' ENTERED AT 16:37:04 ON 17 APR 2003

FILE 'SCISEARCH' ENTERED AT 16:37:04 ON 17 APR 2003

COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'LIFESCI' ENTERED AT 16:37:04 ON 17 APR 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 16:37:04 ON 17 APR 2003

COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOSIS' ENTERED AT 16:37:04 ON 17 APR 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:37:04 ON 17 APR 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 16:37:04 ON 17 APR 2003

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 16:37:04 ON 17 APR 2003

All rights reserved. (2003)

FILE 'ESBIODBASE' ENTERED AT 16:37:04 ON 17 APR 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 16:37:04 ON 17 APR 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:37:04 ON 17 APR 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

75.54

76.38

=> s glcnac phosphotransferase

L8 101 GLCNAC PHOSPHOTRANSFERASE

=> s l8 and (293 or hek293 or cho)

L9 7 L8 AND (293 OR HEK293 OR CHO)

=> dup rem l9

PROCESSING COMPLETED FOR L9

L10 3 DUP REM L9 (4 DUPLICATES REMOVED)

=> d 1-3

L10 ANSWER 1 OF 3 LIFESCI COPYRIGHT 2003 CSA DUPLICATE 1

AN 90:54469 LIFESCI

TI Regulation of glycosylation. Three enzymes compete for a common pool of dolichyl phosphate in vivo.

AU Rosenwald, A.G.; Stoll, J.; Krag, S.S.

CS Dep. Biochem., Johns Hopkins Univ. Sch. Hyg. and Public Health, 615 N. Wolfe St., Baltimore, MD 21205, USA

SO J. BIOL. CHEM., (1990) vol. 265, no. 24, pp. 14544-553.

DT Journal

FS L

LA English

SL English

L10 ANSWER 2 OF 3 LIFESCI COPYRIGHT 2003 CSA

AN 88:24900 LIFESCI

TI A mutant of Chinese hamster ovary cells with a reduction in levels of

dolichyl phosphate available for glycosylation.  
AU Stoll, J.; Krag, S.S.  
CS. Lab. Clin. Stud., Natl. Inst. Alcohol Abuse and Alcoholism, Natl. Inst.  
Health, Bethesda, MD 20892, USA  
SO J. BIOL. CHEM., (1988) vol. 263, no. 22, pp. 10776-773.  
DT Journal  
FS G  
LA English  
SL English

L10 ANSWER 3 OF 3 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 2  
AN 88181835 EMBASE  
DN 1988181835  
TI A mutant of Chinese hamster ovary cells with a reduction in levels of  
dolichyl phosphate available for glycosylation.  
AU Stoll J.; Krag S.S.  
CS Department of Biochemistry, Johns Hopkins University, School of Hygiene  
and Public Health, Baltimore, MD 21205, United States  
SO Journal of Biological Chemistry, (1988) 263/22 (10766-10773).  
ISSN: 0021-9258 CODEN: JBCHA3  
CY United States  
DT Journal  
FS 029 Clinical Biochemistry  
LA English  
SL English

=> d 1-3 kwic

L10 ANSWER 1 OF 3 LIFESCI COPYRIGHT 2003 CSA DUPLICATE 1  
AB . . . hamster ovary cells containing alterations in the levels of  
activity of two enzymes in the oligosaccharyl-P-P-dolichol biosynthetic  
pathway, namely UDP-GlcNAc:dolichyl phosphate:**GlcNAc-  
phosphotransferase** (GlcNAc-1-phosphotransferase) and  
mannosylphosphoryldolichol (Man-P-Dol) synthase. When 3E11 cells (a  
tunicamycin-resistant Chinese hamster ovary line containing 15 times more  
GlcNAc-1-phosphotransferase activity. . .  
UT glycosylation; dolichyl phosphate; enzymatic activity; CHO cells

L10 ANSWER 2 OF 3 LIFESCI COPYRIGHT 2003 CSA  
AB . . . reduced amounts. In vitro assays using membrane preparations  
showed that F2A8 had parental levels of glucosyl-phosphoryldolichol  
synthase and of UDP-GlcNAc:dolichyl phosphate:**GlcNAc-  
phosphotransferase** when the enzymatic determinations were done in  
the presence of exogenous dolichyl phosphate.  
UT CHO cells; dolichyl phosphate; glycosylation; levels; mutants

L10 ANSWER 3 OF 3 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 2  
AB . . . gel electrophoresis. In vitro assays using membrane preparations  
showed that F2A8 had parental levels of glucosylphosphoryldolichol  
synthase and of UDP-GlcNAc:dolichyl phosphate:**GlcNAc-  
phosphotransferase** when the enzymatic determinations were done in  
the presence of exogenous dolichyl phosphate. However, 5-fold less  
glucosylphosphoryldolichol synthase activity was. . .  
CT Medical Descriptors:  
\*cell mutant  
\*protein glycosylation  
cell culture  
cho cell  
hamster  
animal cell  
nonhuman  
\*dolichol phosphate  
\*mannose  
radioisotope

=> dis his

(FILE 'HOME' ENTERED AT 16:18 ON 17 APR 2003)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIODBASE, BIOTECHNO, WPIDS' ENTERED AT 16:14:55 ON 17 APR 2003

L1 206 S FURIN AND REVIEW  
L2 2109 S FURIN/TI  
L3 8 S L1 AND SUBUNIT  
L4 5 DUP REM L3 (3 DUPLICATES REMOVED)  
L5 96 S FURIN AND SUBUNIT AND FUSION  
L6 82 S L5 AND CLEAV?  
L7 20 DUP REM L6 (62 DUPLICATES REMOVED)  
L8 101 S GLCNAC PHOSPHOTRANSFERASE  
L9 7 S L8 AND (293 OR HEK293 OR CHO)  
L10 3 DUP REM L9 (4 DUPLICATES REMOVED)

=> s l8 and (express? or recombina? or dna)

6 FILES SEARCHED...

L11 21 L8 AND (EXPRESS? OR RECOMBINA? OR DNA)

=> dup rem l11

PROCESSING COMPLETED FOR L11

L12 7 DUP REM L11 (14 DUPLICATES REMOVED)

=> d 1-7

L12 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 1

AN 2001:208390 HCAPLUS

DN 134:248843

TI Use of **GlcNAc-phosphotransferase** and phosphodiester  
.alpha.-GlcNAcase in production of highly phosphorylated lysosomal  
hydrolases useful in treatment of lysosomal storage diseases

IN Canfield, William M.

PA USA

SO PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019955	A2	20010322	WO 2000-US21970	20000914
WO 2001019955	A3	20011004		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6534300 B1 20030318 US 2000-635872 20000810

US 6537785 B1 20030325 US 2000-636077 20000810

AU 2000073303 A5 20010417 AU 2000-73303 20000914

BR 2000014514 A 20020723 BR 2000-14514 20000914

EP 1224266 A2 20020724 EP 2000-961335 20000914

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003509043 T2 20030311 JP 2001-523727 20000914

US 2002025550 A1 20020228 US 2001-895072 20010702

US 2002150981 A1 20021017 US 2001-986552 20011109

PRAI US 1999-153831P P 19990914

US 2000-635872 A1 20000810

WO 2000-US21970 W 20000914

L12 ANSWER 2 OF 7 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI

AN 2001-09921 BIOTECHDS

TI Novel N-acetylglucosamine-1-phosphotransferase and N-acetylglucosamine-1-phosphodiester-alpha-N-acetylglucosaminidase, useful for producing

phosphorylated lysosomal H<sub>2</sub>O<sub>2</sub>ase for treating lysosomal storage diseases;

vector-mediated gene transfer and expression in host cell, monoclonal antibody and hybridoma

AU Canfield W M  
PA Canfield W M  
LO Oklahoma City, OK, USA.  
PI WO 2001019955 22 Mar 2001  
AI WO 2000-US21970 14 Sep 2000  
PRAI US 1999-153831 14 Sep 1999  
DT Patent  
LA English  
OS WPI: 2001-290356 [30]

L12 ANSWER 3 OF 7 WPIDS (C) 2003 THOMSON DERWENT

AN 2001-290925 [30] WPIDS

DNN N2001-207764 DNC C2001-089281

TI Producing a post-translationally modified heterologous polypeptide such as immunoglobulin, integrin, addressin, selectin, in plant host system, comprises altering natural post-translational modification abilities of plant.

DC B04 C06 D16 P13

IN BASSUNER, R; MANJUNATH, S; RUSSELL, D

PA (MONS) MONSANTO CO

CYC 94

PI WO 2001029242 A2 20010426 (200130)\* EN 132p C12N015-82

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
NL OA PT SD SE SL SZ TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM  
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC  
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE  
SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AU 2001015736 A 20010430 (200148) C12N015-82

EP 1224309 A2 20020724 (200256) EN C12N015-82

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
RO SE SI

ADT WO 2001029242 A2 WO 2000-US29027 20001020; AU 2001015736 A AU 2001-15736  
20001020; EP 1224309 A2 EP 2000-978257 20001020, WO 2000-US29027 20001020

FDT AU 2001015736 A Based on WO 200129242; EP 1224309 A2 Based on WO 200129242

PRAI US 2000-195282P 20000407; US 1999-160758P 19991021

IC ICM C12N015-82

ICS A01H005-00; C12N009-10

L12 ANSWER 4 OF 7 SCISEARCH COPYRIGHT 2003 ISI (R) DUPLICATE 2

AN 2000:206232 SCISEARCH

GA The Genuine Article (R) Number: 291QD

TI Molecular basis of variant pseudo-Hurler polydystrophy (mucopolipidosis IIIC)

AU RaasRothschild A; CormierDaire V; Bao M; Genin E; Salomon R; Brewer K;  
Zeigler M; Mandel H; Toth S; Roe B; Munnich A; Canfield W M (Reprint)

CS UNIV OKLAHOMA, HLTH SCI CTR, STANTON L YOUNG BIOMED RES CTR 411, WK WARREN  
MED RES INST, OKLAHOMA CITY, OK 73104 (Reprint); UNIV OKLAHOMA, HLTH SCI  
CTR, STANTON L YOUNG BIOMED RES CTR 411, WK WARREN MED RES INST, OKLAHOMA  
CITY, OK 73104; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, OKLAHOMA CITY, OK  
73104; HADASSAH HEBREW UNIV HOSP, DEPT HUMAN GENET, IL-91120 JERUSALEM,  
ISRAEL; HOP NECKER ENFANTS MALAD, INSERM, U393, UNITE RECH HANDICAPS GENET  
ENFANT, F-75015 PARIS, FRANCE; INSERM, U155, F-75016 PARIS, FRANCE; RAMBAM  
MED CTR, DEPT PEDIAT, IL-35254 HAIFA, ISRAEL; UNIV OKLAHOMA, DEPT CHEM,  
NORMAN, OK 73019

CYA USA; ISRAEL; FRANCE

SO JOURNAL OF CLINICAL INVESTIGATION, (MAR 2000) Vol. 105, No. 5, pp.  
673-681.

Publisher: AMER SOC CLINICAL INVESTIGATION INC, ROOM 4570 KRESGE I, 200  
ZINA PITCHER PLACE, ANN ARBOR, MI 48109-0560.

ISSN: 0021-9738.

DT Article; Journal

FS LIFE

LA English

REC Reference Count: 35

L12 ANSWER 5 OF 7 MEDLINE DUPLICATE 3  
 AN 1998019241 MEDLINE  
 DN 98019241 PubMed ID: 9353330  
 TI UDP-GlcNAc:Ser-protein N-acetylglucosamine-1-phosphotransferase from Dictyostelium discoideum recognizes serine-containing peptides and eukaryotic cysteine proteinases.  
 AU Mehta D P; Etchison J R; Wu R; Freeze H H  
 CS The Burnham Institute, La Jolla Cancer Research Center, La Jolla, California 92037, USA.  
 NC R01 32485  
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1997 Nov 7) 272 (45) 28638-45.  
 Journal code: 2985121R. ISSN: 0021-9258.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199712  
 ED Entered STN: 19980109  
 Last Updated on STN: 20000303  
 Entered Medline: 19971212

L12 ANSWER 6 OF 7 SCISEARCH COPYRIGHT 2003 ISI (R)  
 AN 96:911001 SCISEARCH  
 GA The Genuine Article (R) Number: VW686  
 TI Bovine UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase .1. Purification and subunit structure  
 AU Bao M; Booth J L; Elmendorf B J; Canfield W M (Reprint)  
 CS UNIV OKLAHOMA, HLTH SCI CTR, WK WARREN MED RES INST, BSEB 302, 941 STANTON L YOUNG BLVD, OKLAHOMA CITY, OK 73104 (Reprint); UNIV OKLAHOMA, HLTH SCI CTR, WK WARREN MED RES INST, OKLAHOMA CITY, OK 73104; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, OKLAHOMA CITY, OK 73104  
 CYA USA  
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (6 DEC 1996) Vol. 271, No. 49, pp. 31437-31445.  
 Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814.  
 ISSN: 0021-9258.  
 DT Article; Journal  
 FS LIFE  
 LA English  
 REC Reference Count: 35  
 \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L12 ANSWER 7 OF 7 MEDLINE DUPLICATE 4  
 AN 92283889 MEDLINE  
 DN 92283889 PubMed ID: 1317874  
 TI Characterization of UDP-N-acetylglucosamine:glycoprotein N-acetylglucosamine-1-phosphotransferase from Acanthamoeba castellanii.  
 AU Ketcham C M; Kornfeld S  
 CS Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.  
 NC CA 08759 (NCI)  
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1992 Jun 5) 267 (16) 11654-9.  
 Journal code: 2985121R. ISSN: 0021-9258.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199207  
 ED Entered STN: 19920717  
 Last Updated on STN: 19970203  
 Entered Medline: 19920706

=> d 1-7 kwic

L12 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 1

TI Use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in production of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases

AB The lysosomal targeting pathway enzymes **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase and uses in prodn. of highly phosphorylated lysosomal hydrolases that can be used to treat lysosomal storage diseases, are disclosed. Generally, the nucleic acid mols. coding for the enzymes are incorporated into **expression** vectors that are used to transfect host cells that **express** the enzymes. The **expressed** enzymes are recovered using monoclonal antibodies capable of selectively binding to bovine **GlcNAc-phosphotransferase** and to bovine phosphodiester .alpha.-GlcNAcase. Lysosomal hydrolases having high mannose structures are treated with **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase resulting in the prodn. of asparagine-linked oligosaccharides that are highly modified with mannose 6-phosphate ("M6P"). The treated. . .

ST **GlcNAc phosphotransferase** phosphodiester alpha GlcNAcase phosphorylation lysosomal hydrolase; lysosomal storage disease enzyme replacement therapy hydrolase

IT Disease, animal  
(Aspartylglucosaminuria; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal  
(Farber Lipogranulomatosis; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal  
(Fucosidosis; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Gangliosidosis  
(GM1 gangliosidosis; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Mucopolysaccharidosis  
(Hunter's syndrome; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Mucopolysaccharidosis  
(Hurler's syndrome; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Brain, disease  
(Krabbe's disease; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Mucopolysaccharidosis  
(Maroteaux-Lamy syndrome; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal  
(Morquio Syndrome; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal  
(Mucopolipidosis IV; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Gangliosidosis  
(Sandhoff's disease; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal  
(Sanfilippo A; use of **GlcNAc-phosphotransferase** and

phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal

(Schindler Disease; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal

(Sialidosis; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal

(Sly Syndrome; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Gangliosidosis

(Tay-Sachs disease; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal

(Wolman's; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Oligosaccharides, biological studies

RL: BOC (Biological occurrence); BSU (Biological study, unclassified);

BIOL (Biological study); OCCU (Occurrence)

(asparagine-linked, in lysosomal hydrolase; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Sialic acids

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(galactosialidosis; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Brain, disease

(metachromatic leukodystrophy; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Antibodies

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(monoclonal; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Phosphorylation, biological

(protein; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Enzymes, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(replacement therapy; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Glycogen storage disease

(type II; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Fabry disease

Gaucher disease

Genetic vectors

Hybridoma

Lysosomal storage disease

Lysosome

Molecular cloning

Niemann-Pick disease

Protein sequences



cdNA sequences

(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Antibodies

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Gangliosides

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 9012-33-3

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(A; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 9068-67-1, Sulfatase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Deficiency, Multiple; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 9027-41-2, Hydrolase 9031-54-3, Sphingomyelinase

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(Lysosomal; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 253334-78-0P, N-Acetylglucosamine-1-phosphodiester .alpha.-N-Acetylglucosaminidase (human)

RL: BPN (Biosynthetic preparation); CAT (Catalyst use); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 3458-28-4, Mannose

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)

(in lysosomal hydrolase; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 9068-25-1, .alpha.-1,2-Mannosidase

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(inhibitor; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 528-04-1

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(transfer of N-acetyl glucosamine-1-phosphate from; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 28446-21-1, N-Acetyl glucosamine-1-phosphate

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(transfer of; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated

lysosomal hydrolases used in treatment of lysosomal storage diseases)

IT 331288-42-7 331288-43-8, 2: PN: WO0119955 PAGE: 53 unclaimed DNA  
331288-44-9, 3: PN: WO0119955 PAGE: 54 unclaimed DNA  
331288-45-0, 4: PN: WO0119955 PAGE: 54 unclaimed DNA  
331288-46-1 331288-47-2 331288-48-3 331288-49-4 331288-50-7  
331288-51-8 331288-52-9 331288-53-0 331288-54-1, 16: PN: WO0119955  
PAGE: 50 unclaimed DNA 331288-55-2 331288-56-3  
RL: PRP (Properties)

(unclaimed nucleotide sequence; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 331443-59-5 331443-60-8  
RL: PRP (Properties)

(unclaimed protein sequence; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 331434-83-4 331434-84-5 331434-86-7 331434-87-8 331434-89-0  
331434-90-3 331434-91-4 331434-93-6 331434-95-8 331434-97-0  
331434-99-2 331435-01-9 331435-02-0  
RL: PRP (Properties)

(unclaimed sequence; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 75788-84-0P, E.C. 3.1.4.45 84012-69-1P, E.C. 2.7.8.17  
RL: BPN (Biosynthetic preparation); CAT (Catalyst use); PRP (Properties);  
PUR (Purification or recovery); BIOL (Biological study); PREP  
(Preparation); USES (Uses)

(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 7512-17-6, N-Acetylglucosamine  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
(Biological study); PROC (Process)

(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 9001-42-7, .alpha.-Glucosidase 9001-45-0, .beta.-Glucuronidase  
9001-62-1 9001-67-6, Neuraminidase 9016-17-5, Arylsulfatase  
9025-35-8, .alpha.-Galactosidase A 9025-62-1, Arylsulfatase C  
9027-89-8, Galactocerebrosidase 9030-36-8, Galactose 6-sulfatase  
9031-11-2 9037-65-4, .alpha.-Fucosidase 9068-68-2, Arylsulfatase A  
9073-56-7, .alpha.-Iduronidase 9075-63-2, .alpha.-N-Acetyl  
galactosaminidase 9077-06-9, Heparan N-sulfatase 37228-64-1,  
Glucocerebrosidase .beta.-Glucosidase 37288-40-7, N-Acetyl-.alpha.-  
glucosaminidase 37289-06-8, Acid Ceramidase 50936-59-9, Iduronate  
2-sulfatase 55354-43-3, Arylsulfatase B 56467-83-5, Ceramidase  
59299-00-2, N-Acetylgalactosamine-6-sulfatase 60320-99-2,  
N-Acetylglucosamine-6-sulfatase 79955-83-2, Acetyl CoA-.alpha.-  
glucosaminide N-acetyl transferase 83534-39-8, N-Glycosidase F  
RL: BPR (Biological process); BSU (Biological study, unclassified); THU  
(Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 3672-15-9, Mannose 6-phosphate  
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL  
(Biological study); FORM (Formation, nonpreparative)

(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 84444-90-6, Deoxymannojirimycin 109944-15-2, Kifunensine 149674-55-5,  
D-Mannoamidrazone 155501-85-2  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
(Uses)

(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

L12 ANSWER 2 OF 7 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI  
TI. Novel N-acetylglucosamine-1-phosphotransferase and N-acetylglucosamine-1-phosphodiester-alpha-N-acetylglucosaminidase, useful for producing phosphorylated lysosomal hydrolase for treating lysosomal storage diseases;

vector-mediated gene transfer and **expression** in host cell, monoclonal antibody and hybridoma

AB Isolated human N-acetylglucosamine-1-phosphotransferase (**GlcNAc-phosphotransferase**) and N-acetylglucosamine-1-phosphodiester-alpha-N-acetylglucosaminidase (phosphodiester-alpha-GlcNAcase, EC-3.1.4.45), is new. Also claimed are: nucleic acids encoding **GlcNAc-phosphotransferase** and phosphodiester alpha-GlcNAcase; vector containing the nucleic acids; host cell containing the vector; preparation of **GlcNAc-phosphotransferase** or phosphodiester-alpha-GlcNAcase; nucleic acids encoding mouse **GlcNAc-phosphotransferase** which has an alpha-subunit, beta-subunit and gamma-subunit and mouse phosphodiester-alpha-GlcNAcase; vector and host cell transformed with this vector; preparation of mouse **GlcNAc-phosphotransferase** and phosphodiester-alpha-GlcNAcase; lysosomal hydrolase containing a mannose-6-phosphate; phosphorylated lysosomal hydrolase; producing a high mannose lysosomal hydrolase; high mannose lysosomal hydrolase; and monoclonal antibodies produced by PT18 hybridoma (ATCC PTA 2432) or UC1 hybridoma (ATCC 2431). The **GlcNAc-phosphotransferase** and phosphodiester-alpha-GlcNAcase are useful for producing a phosphorylated lysosomal hydrolase for treating lysosomal storage disease. (91pp)

CT HUMAN, MOUSE **RECOMBINANT N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE, N-ACETYLGLUCOSAMINE-1-PHOSPHODIESTER-ALPHA-N-ACETYLGLUCOSAMINIDASE PREP., VECTOR-MEDIATED GENE TRANSFER, EXPRESSION IN HOST CELL, MONOCLONAL ANTIBODY, HYBRIDOMA, APPL. PHOSPHORYLATED LYSOSOMAL HYDROLASE PREP., LYSOSOMAL STORAGE DISEASE THERAPY ANIMAL MAMMAL ENZYME EC-3.1.4.45 DNA SEQUENCE PROTEIN SEQUENCE CELL CULTURE (VOL.20, NO.19)**

L12 ANSWER 3 OF 7 WPIDS (C) 2003 THOMSON DERWENT

AB . . .  
new.

DETAILED DESCRIPTION - Producing (M1) a post-translationally (PT) modified heterologous polypeptide in a plant host system (I) comprising:

(a) **expressing** the heterologous polypeptide, where the cells of (I) have been transformed with one or more **expression** vectors containing a nucleic acid sequence encoding a heterologous polypeptide;

(b) **expressing** a PT modifying enzyme, where the cells of (I) have been transformed with an **expression** vector containing a nucleic acid sequence encoding a PT modifying enzyme;

(c) **expressing** a heterologous polypeptide and a PT modifying enzyme where the cells of (I) have been transformed with a first **expression** vector containing a nucleic acid sequence encoding a heterologous polypeptide and a second **expression** vector containing a nucleic acid sequence encoding a PT modifying enzyme; and

(d) cross-pollinating a first (I) whose cells have been transformed with a first **expression** vector containing a nucleic acid sequence encoding a heterologous polypeptide, and a second (I), where the cells of (I) have been transformed with a second **expression** vector containing a nucleic acid sequence encoding a PT modifying enzyme.

INDEPENDENT CLAIMS are also included for the following:

(1) (I) **expressing** a PT-modified heterologous polypeptide where the natural PT modification abilities of (I) have been altered where

(a) the cells of (I) have been transformed with:

(i) an **expression** vector comprising a nucleic acid sequence encoding a heterologous polypeptide;

(ii) an **expression** vector comprising a PT modifying enzyme;

(iii) a first **expression** vector comprising a nucleic acid sequence encoding a heterologous polypeptide and a second **expression** vector comprising a nucleic acid sequence encoding a PT modifying enzyme;

(b) (I) that produces modified heterologous polypeptide and expresses a first expression vector comprising a nucleic acid sequence encoding a heterologous polypeptide and a second express vector comprising a nucleic acid sequence encoding a PT modifying enzyme;

(2) a plant (II) produced by M1;

(3) a seed produced from (II); and

(4) an expression vector comprising one or more nucleic acid sequences encoding one or more of heterologous polypeptide and a PT modifying enzyme.. . .

TECH. . . . one or more nucleic acid sequences encoding a PT modification enzyme such as glycoprotein glycosyltransferases, GlcNAc-1-phosphotransferase, GlcNAc-1-phosphodiester-N-acetylglucosaminidase, glycosidases, exoglycosidases, endoglycosidases, **GlcNAc phosphotransferase**, protein kinases, 3'-phosphoadenosyl-5'-phosphosulfate, prolyl hydroxylase and lysyl hydroxylase. Alternately, the process of altering the natural PT-modification abilities of the (I). . . be carried out by transforming (I) comprising a nucleic acid sequence that encodes an antisense nucleic acid (antisense RNA or DNA) which inhibits the expression of at least one endogenous plant protein that comprises a plant specific-PT modification enzyme such as N-acetyl glucosaminyl transferase 1. . . cell suspension culture). Preferred Nucleic Acid: The nucleic acid sequences encoding the heterologous polypeptide are contained with one or more expression vectors that further comprise a signal peptide functional in the plant host system, a promoter functional in the plant host. . . .

L12 ANSWER 4 OF 7 SCISEARCH COPYRIGHT 2003 ISI (R) DUPLICATE 2  
AB . . . disease of lysosomal hydrolase trafficking. Unlike the related diseases, mucopolipidosis II and IIIA, the enzyme affected in mucopolipidosis IIIC (N-Acetylglucosamine-1-phosphotransferase [**GlcNAc-phosphotransferase**]) retains full transferase activity on synthetic substrates but lacks activity on lysosomal hydrolases. Bovine **GlcNAc-phosphotransferase** has recently been isolated as a multisubunit enzyme with the subunit structure alpha(2)beta(2)gamma(2). We cloned the cDNA for the human. . . .  
STP KeyWords Plus (R): UDP-N-ACETYLGLUCOSAMINE; LYSOSOMAL-ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; I-CELL DISEASE; LINKAGE ANALYSIS; SEQUENCE; FIBROBLASTS; PHOSPHORYLATION; HETEROGENEITY; RECEPTORS; DNA

L12 ANSWER 5 OF 7 MEDLINE DUPLICATE 3  
AB Phosphoglycosylation catalyzed by UDP-GlcNAc:Ser-protein N-acetylglucosamine-1-phosphotransferase (Ser:**GlcNAc phosphotransferase**) adds GlcNAcalpha-1-P to peptidyl-Ser of selected Dictyostelium discoideum proteins. Lysosomal cysteine proteinase (CP), proteinase-1(CP7), is the major phosphoglycosylated protein in. . . destroys the inhibitory potential of all CPs showing that transferase recognizes a conformation-dependent feature that is shared by all. Proteinase-1(CP7) expressed in Escherichia coli lacks GlcNAc-1-P, but it is a substrate for Ser:**GlcNAc phosphotransferase**, Km = 5.6 microM. Thus, Ser:**GlcNAc phosphotransferase** recognizes both acceptor peptide sequences and a conformational feature of eukaryotic CPs. This may be physiologically important for establishing or. . . .  
CT . . . Support, U.S. Gov't, P.H.S.  
Chromatography, High Pressure Liquid  
\*Cysteine Endopeptidases: ME, metabolism  
\*Dictyostelium: EN, enzymology  
Glycosylation  
\*Peptides: ME, metabolism  
Phosphorylation  
Recombinant Fusion Proteins: ME, metabolism  
\*Serine: ME, metabolism  
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization  
Substrate Specificity  
\*Transferases (Other Substituted Phosphate Groups):. . . .  
CN 0 (Peptides); 0 (Recombinant Fusion Proteins); EC 2.7.8

(Transferases (Other Substituted Phosphate Groups)); EC 2.7.  
(UDP-GlcNAc - Ser-protein N-acetylglucosamine-1-phosphotransferase); EC  
3.4.22 (Cysteine Endopeptidases)

L12 ANSWER 6 OF 7 SCISEARCH COPYRIGHT 2003 ISI (R)

AB UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase (**GlcNAc-phosphotransferase**) catalyzes the initial step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized. . . green 19-agarose, and Superose 6, The partially purified enzyme was used to generate a panel of murine monoclonal antibodies, The anti-**GlcNAc-phosphotransferase** monoclonal antibody PT18 was coupled to a solid support and used to immunopurify the enzyme similar to 480,000-fold to apparent. . . a combination of analytical gel filtration chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and amino-terminal sequencing. The data indicate that bovine **GlcNAc-phosphotransferase** is a 540,000-Da complex composed of disulfide-linked homodimers of 166,000- and 51,000-Da subunits and two identical, noncovalently associated 56,000-Da subunits.

STP KeyWords Plus (R): I-CELL DISEASE; GLYCOPROTEIN N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; RAT-LIVER; CDNA CLONING; PROTEINS; ACETYLGLUCOSAMINYLPHOSPHOTRANSFERASE; PHOSPHODIESTERASE; PHOSPHORYLATION; **EXPRESSION**; IDENTIFICATION

L12 ANSWER 7 OF 7 MEDLINE DUPLICATE 4

AB The kinetic properties of UDP-N-acetylglucosamine:glycoprotein N-acetylglucosamine-1-phosphotransferase (**GlcNAc-phosphotransferase**) partially purified from the soil amoeba *Acanthamoeba castellanii* have been studied. The transferase phosphorylated the lysosomal enzymes uteroferrin and cathepsin. . . Deglycosylated RNase (RNase A) did not inhibit the phosphorylation of RNase B or uteroferrin. These results indicate that purified amoeba **GlcNAc-phosphotransferase** recognizes a protein domain present on lysosomal enzymes but absent in most nonlysosomal glycoproteins. The transferase also exhibited a marked. . . pathway for the mannose 6-phosphate recognition marker. We conclude that *A. castellanii* does not utilize the phosphomannosyl sorting pathway despite **expression** of very high levels of **GlcNAc-phosphotransferase**.

=> dis his

(FILE 'HOME' ENTERED AT 16:12:18 ON 17 APR 2003)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIODBASE, BIOTECHNO, WPIDS' ENTERED AT 16:14:55 ON 17 APR 2003

L1 206 S FURIN AND REVIEW  
L2 2109 S FURIN/TI  
L3 8 S L1 AND SUBUNIT  
L4 5 DUP REM L3 (3 DUPLICATES REMOVED)  
L5 96 S FURIN AND SUBUNIT AND FUSION  
L6 82 S L5 AND CLEAV?  
L7 20 DUP REM L6 (62 DUPLICATES REMOVED)  
L8 101 S GLCNAC PHOSPHOTRANSFERASE  
L9 7 S L8 AND (293 OR HEK293 OR CHO)  
L10 3 DUP REM L9 (4 DUPLICATES REMOVED)  
L11 21 S L8 AND (EXPRESS? OR RECOMBINA? OR DNA)  
L12 7 DUP REM L11 (14 DUPLICATES REMOVED)

=> s l8 (5a) human

5 FILES SEARCHED...

L13 10 L8 (5A) HUMAN

=> dup rem l13

PROCESSING COMPLETED FOR L13

L14 5 DUP REM L13 (5 DUPLICATES REMOVED)

L14 ANSWER 1 OF 5 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI  
 AN 2001-09921 BIOTECHDS  
 TI Novel N-acetylglucosamine-1-phosphotransferase and N-acetylglucosamine-1-phosphodiester-alpha-N-acetylglucosaminidase, useful for producing phosphorylated lysosomal hydrolase for treating lysosomal storage diseases;  
 vector-mediated gene transfer and expression in host cell, monoclonal antibody and hybridoma  
 AU Canfield W M  
 PA Canfield W M  
 LO Oklahoma City, OK, USA.  
 PI WO 2001019955 22 Mar 2001  
 AI WO 2000-US21970 14 Sep 2000  
 PRAI US 1999-153831 14 Sep 1999  
 DT Patent  
 LA English  
 OS WPI: 2001-290356 [30]

L14 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2003 ACS  
 AN 2001:208390 HCAPLUS  
 DN 134:248843  
 TI Use of GlcNAc-phosphotransferase and phosphodiester .alpha.-GlcNAcase in production of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases  
 IN Canfield, William M.  
 PA USA  
 SO PCT Int. Appl., 91 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019955	A2	20010322	WO 2000-US21970	20000914
	WO 2001019955	A3	20011004		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6534300	B1	20030318	US 2000-635872	20000810
	US 6537785	B1	20030325	US 2000-636077	20000810
	AU 2000073303	A5	20010417	AU 2000-73303	20000914
	BR 2000014514	A	20020723	BR 2000-14514	20000914
	EP 1224266	A2	20020724	EP 2000-961335	20000914
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003509043	T2	20030311	JP 2001-523727	20000914
	US 2002025550	A1	20020228	US 2001-895072	20010702
	US 2002150981	A1	20021017	US 2001-986552	20011109
PRAI	US 1999-153831P	P	19990914		
	US 2000-635872	A1	20000810		
	WO 2000-US21970	W	20000914		

L14 ANSWER 3 OF 5 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 1  
 AN 1991:410623 BIOSIS  
 DN BA92:77588  
 TI ELEVATED CARBOHYDRATE PHOSPHOTRANSFERASE ACTIVITY IN HUMAN HEPATOMA AND PHOSPHORYLATION OF CATHEPSIN D.  
 AU OHHIRA M; GASA S; MAKITA A; SEKIYA C; NAMIKI M  
 CS BIOCHEM. LAB., CANCER INST., HOKKAIDO UNIV. SCH. MED., KITA-KU N15 W7, SAPPORO 060, JPN.  
 SO BR J CANCER, (1991) 63 (6), 905-908.

CODEN: BJCAAI. ISSN: 0007-0000.

FS BA; OLD  
LA English

L14 ANSWER 4 OF 5 SCISEARCH COPYRIGHT 2003 ISI (R)  
AN 91:384702 SCISEARCH  
GA The Genuine Article (R) Number: FU823  
TI ELEVATED CARBOHYDRATE PHOSPHOTRANSFERASE ACTIVITY IN HUMAN HEPATOMA AND  
PHOSPHORYLATION OF CATHEPSIN-D  
AU OHHIRA M; GASA S (Reprint); MAKITA A; SEKIYA C; NAMIKI M  
CS HOKKAIDO UNIV, SCH MED, INST CANC, BIOCHEM LAB, KITA KU, N15W7, SAPPORO,  
HOKKAIDO 060, JAPAN; ASHIKAWA MED COLL, DEPT INTERNAL MED 3, ASAHIKAWA  
070, JAPAN  
CYA JAPAN  
SO BRITISH JOURNAL OF CANCER, (1991) Vol. 63, No. 6, pp. 905-908.  
DT Article; Journal  
FS LIFE  
LA ENGLISH  
REC Reference Count: 22  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L14 ANSWER 5 OF 5 MEDLINE DUPLICATE 2  
AN 87166059 MEDLINE  
DN 87166059 PubMed ID: 3031074  
TI Glucose-1-phosphotransferase and N-acetylglucosamine-1-phosphotransferase  
have distinct acceptor specificities.  
AU Hiller A M; Koro L A; Marchase R B  
NC EY 06714 (NEI)  
GM 31381 (NIGMS)  
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1987 Mar 25) 262 (9) 4377-81.  
Journal code: 2985121R. ISSN: 0021-9258.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 198705  
ED Entered STN: 19900303  
Last Updated on STN: 20000303  
Entered Medline: 19870506

=> dis his

(FILE 'HOME' ENTERED AT 16:12:18 ON 17 APR 2003)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS,  
NTIS, ESBIODBASE, BIOTECHNO, WPIDS' ENTERED AT 16:14:55 ON 17 APR 2003

L1 206 S FURIN AND REVIEW  
L2 2109 S FURIN/TI  
L3 8 S L1 AND SUBUNIT  
L4 5 DUP REM L3 (3 DUPLICATES REMOVED)  
L5 96 S FURIN AND SUBUNIT AND FUSION  
L6 82 S L5 AND CLEAV?  
L7 20 DUP REM L6 (62 DUPLICATES REMOVED)  
L8 101 S GLCNAC PHOSPHOTRANSFERASE  
L9 7 S L8 AND (293 OR HEK293 OR CHO)  
L10 3 DUP REM L9 (4 DUPLICATES REMOVED)  
L11 21 S L8 AND (EXPRESS? OR RECOMBINA? OR DNA)  
L12 7 DUP REM L11 (14 DUPLICATES REMOVED)  
L13 10 S L8 (5A) HUMAN  
L14 5 DUP REM L13 (5 DUPLICATES REMOVED)

=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
161.07	161.91

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-0.65

65

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 16:59:29 ON 17 APR 2003



Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1800exs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Jun 03 New e-mail delivery for search results now available  
NEWS 4 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 5 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 6 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 7 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 8 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 9 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 10 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 11 Oct 24 BEILSTEIN adds new search fields  
NEWS 12 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 13 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 14 Nov 25 More calculated properties added to REGISTRY  
NEWS 15 Dec 04 CSA files on STN  
NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 17 Dec 17 TOXCENTER enhanced with additional content  
NEWS 18 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 19 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
ENERGY, INSPEC  
NEWS 20 Feb 13 CANCERLIT is no longer being updated  
NEWS 21 Feb 24 METADEX enhancements  
NEWS 22 Feb 24 PCTGEN now available on STN  
NEWS 23 Feb 24 TEMA now available on STN  
NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation  
NEWS 25 Feb 26 PCTFULL now contains images  
NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results  
NEWS 27 Mar 19 APOLLIT offering free connect time in April 2003  
NEWS 28 Mar 20 EVENTLINE will be removed from STN  
NEWS 29 Mar 24 PATDPAFULL now available on STN  
NEWS 30 Mar 24 Additional information for trade-named substances without  
structures available in REGISTRY  
NEWS 31 Mar 24 Indexing from 1957 to 1966 added to records in CA/CAPLUS  
NEWS 32 Apr 11 Display formats in DGENE enhanced  
NEWS 33 Apr 14 MEDLINE Reload  
NEWS 34 Apr 17 Polymer searching in REGISTRY enhanced  
  
NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:12:18 ON 17 APR 2003

=> fil .eliz

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.84

0.84

FILE 'MEDLINE' ENTERED AT 16:14:55 ON 17 APR 2003

FILE 'SCISEARCH' ENTERED AT 16:14:55 ON 17 APR 2003

COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'LIFESCI' ENTERED AT 16:14:55 ON 17 APR 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 16:14:55 ON 17 APR 2003

COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOSIS' ENTERED AT 16:14:55 ON 17 APR 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:14:55 ON 17 APR 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 16:14:55 ON 17 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 16:14:55 ON 17 APR 2003

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2003)

FILE 'ESBIOBASE' ENTERED AT 16:14:55 ON 17 APR 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 16:14:55 ON 17 APR 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:14:55 ON 17 APR 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

=> s furin and review

L1 206 FURIN AND REVIEW

=> s furin/ti

L2 2109 FURIN/TI

=> s l1 and subunit

L3 8 L1 AND SUBUNIT

=> dup rem l3

PROCESSING COMPLETED FOR L3

L4 5 DUP REM L3 (3 DUPLICATES REMOVED)

=> d 1-5

L4 ANSWER 1 OF 5 LIFESCI

COPYRIGHT 2003 CSA

AN 2001:24367 LIFESCI

TI Transgenic animal bioreact  
AU Houdebine, L.M.  
CS Unite de Biologie du Developpement et Biotechnologie, Institut National de  
la Recherche Agronomique, 78352 Jouy-en-Josas Cedex, France; E-mail:  
houdebine@biotec.jouy.inra.fr  
SO Transgenic Research [Transgenic Res.], (20000800) vol. 9, no. 4-5, pp.  
305-320. Special Issue: Frontiers in Transgenic Research..  
ISSN: 0962-8819.  
DT Journal  
FS W2  
LA English  
SL English

L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2003 ACS  
AN 2001:83194 HCAPLUS  
DN 135:17605

TI Amyloidogenesis in familial British dementia is associated with a genetic  
defect on chromosome 13  
AU Ghiso, J.; Vidal, R.; Rostagno, A.; Miravalle, L.; Holton, J. L.; Mead,  
S.; Revesz, T.; Plant, G.; Frangione, B.  
CS Department of Pathology, New York University School of Medicine, New York,  
NY, 10016, USA  
SO Annals of the New York Academy of Sciences (2000), 920(Molecular Basis of  
Dementia), 84-92  
CODEN: ANYAA9; ISSN: 0077-8923  
PB New York Academy of Sciences  
DT Journal; General Review  
LA English

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2003 ACS  
AN 1999:443876 HCAPLUS  
DN 131:241113

TI The polymorphism of the Ebola virus glycoprotein and its potential role in  
pathogenesis  
AU Klenk, Hans-Dieter; Volchkov, Viktor E.; Volchkova, Valentina A.;  
Feldmann, Heinz  
CS Institut fur Virologie Philipps-Universitat Marburg, Marburg, D-35011,  
Germany  
SO Nova Acta Leopoldina (1999), 78(307, Problems of Relevant Infectious  
Diseases), 141-149  
CODEN: NOALA4; ISSN: 0369-5034  
PB Deutsche Akademie der Naturforscher Leopoldina  
DT Journal; General Review  
LA German

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
AN 1998085973 EMBASE

TI Molecular diversity in neurosecretion: Reflections on the hypothalamo-  
neurohypophysial system.  
AU Gainer H.; Chin H.  
CS H. Gainer, Laboratory of Neurochemistry, Natl. Inst. Neurol.  
Disorders/Stroke, Building 36, 9000 Rockville Pike, Bethesda, MD 20892,  
United States  
SO Cellular and Molecular Neurobiology, (1998) 18/2 (211-230).  
Refs: 129  
ISSN: 0272-4340 CODEN: CMNEDI  
CY United States  
DT Journal; General Review  
FS 003 Endocrinology  
029 Clinical Biochemistry  
LA English  
SL English

L4 ANSWER 5 OF 5 MEDLINE  
AN 1998065022 MEDLINE

DUPLICATE 1

DN 98065022 PubMed ID: 9414  
TI Three-dimensional structure of the zona pellucida.  
AU Green D P  
CS Department of Anatomy and Structural Biology, School of Medical Sciences,  
University of Otago Medical School, Dunedin, New Zealand.  
SO REVIEWS OF REPRODUCTION, (1997 Sep) 2 (3) 147-56. Ref: 61  
Journal code: 9602351. ISSN: 1359-6004.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals  
EM 199801  
ED Entered STN: 19980129  
Last Updated on STN: 19980129  
Entered Medline: 19980115

=> dis his

(FILE 'HOME' ENTERED AT 16:12:18 ON 17 APR 2003)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS,  
NTIS, ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 16:14:55 ON 17 APR 2003

L1 206 S FURIN AND REVIEW  
L2 2109 S FURIN/TI  
L3 8 S L1 AND SUBUNIT  
L4 5 DUP REM L3 (3 DUPLICATES REMOVED)

=> s furin and subunit and fusion  
L5 96 FURIN AND SUBUNIT AND FUSION

=> s l5 and cleav?  
L6 82 L5 AND CLEAV?

=> dup rem l6  
PROCESSING COMPLETED FOR L6  
L7 20 DUP REM L6 (62 DUPLICATES REMOVED)

=> d 1-10

L7 ANSWER 1 OF 20 MEDLINE DUPLICATE 1  
AN 2002430489 MEDLINE  
DN 22174911 PubMed ID: 12186905  
TI **Cleavage** at the **furin** consensus sequence RAR/KR(109)  
and presence of the intervening peptide of the respiratory syncytial virus  
**fusion** protein are dispensable for virus replication in cell  
culture.  
AU Zimmer Gert; Conzelmann Karl-Klaus; Herrler Georg  
CS Institut fur Virologie, Tierarztliche Hochschule Hannover, D-30559  
Hannover, Germany.  
SO JOURNAL OF VIROLOGY, (2002 Sep) 76 (18) 9218-24.  
Journal code: 0113724. ISSN: 0022-538X.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200210  
ED Entered STN: 20020821  
Last Updated on STN: 20021003  
Entered Medline: 20021002

L7 ANSWER 2 OF 20 MEDLINE DUPLICATE 2  
AN 2002199772 MEDLINE  
DN 21930153 PubMed ID: 11932382  
TI Amino-terminal precursor sequence modulates canine distemper virus  
**fusion** protein function.  
AU von Messling Veronika; Cattaneo Roberto

CS Molecular Medicine Program Mayo Clinic, Rochester, Minnesota 55905, USA.  
SO JOURNAL OF VIROLOGY, (2002 May) 76 (9) 4172-80.  
Journal code: 0113724. ISSN: 0022-538X.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200205  
ED Entered STN: 20020405  
Last Updated on STN: 20020511  
Entered Medline: 20020510

L7 ANSWER 3 OF 20 MEDLINE DUPLICATE 3  
AN 2002131171 MEDLINE  
DN 21851071 PubMed ID: 11861826  
TI Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.  
AU Binley James M; Sanders Rogier W; Master Aditi; Cayanan Charmagne S; Wiley Cheryl L; Schiffner Linnea; Travis Bruce; Kuhmann Shawn; Burton Dennis R; Hu Shiu-Lok; Olson William C; Moore John P  
CS Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA.. jbinley@scripps.edu  
NC AI45463 (NIAID)  
AI47735 (NIAID)  
AI49566 (NIAID)  
AI49764 (NIAID)  
SO JOURNAL OF VIROLOGY, (2002 Mar) 76 (6) 2606-16.  
Journal code: 0113724. ISSN: 0022-538X.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200203  
ED Entered STN: 20020228  
Last Updated on STN: 20020403  
Entered Medline: 20020329

L7 ANSWER 4 OF 20 MEDLINE DUPLICATE 4  
AN 2001690572 MEDLINE  
DN 21602548 PubMed ID: 11739683  
TI **Furin** is involved in baculovirus envelope **fusion** protein activation.  
AU Westenbergh Marcel; Wang Hualin; IJkel Wilfred F J; Goldbach Rob W; Vlak Just M; Zuidema Douwe  
CS Laboratory of Virology, Wageningen University and Research Center, 6709 PD Wageningen, The Netherlands.  
SO JOURNAL OF VIROLOGY, (2002 Jan) 76 (1) 178-84.  
Journal code: 0113724. ISSN: 0022-538X.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200201  
ED Entered STN: 20011213  
Last Updated on STN: 20020125  
Entered Medline: 20020110

L7 ANSWER 5 OF 20 MEDLINE DUPLICATE 5  
AN 2002003594 MEDLINE  
DN 21623835 PubMed ID: 11752701  
TI Multiple glycosylated forms of the respiratory syncytial virus **fusion** protein are expressed in virus-infected cells.  
AU Rixon Helen W McL; Brown Craig; Brown Gaie; Sugrue Richard J  
CS MRC Virology Unit, Institute of Virology, Church Street, Glasgow G11 5JR, UK.  
SO JOURNAL OF GENERAL VIROLOGY, (2002 Jan) 83 (Pt 1) 61-6.  
Journal code: 0077340. ISSN: 0022-1317.  
CY England: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)

LA English  
FS Priority Journals  
EM 200202  
ED Entered STN: 20020102  
Last Updated on STN: 20020220  
Entered Medline: 20020219

L7 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 6  
AN 2001:636263 HCAPLUS  
DN 135:176419  
TI Methods for identifying candidate polynucleotide molecules encoding a  
protease using viral display package comprising chimeric envelope protein  
IN Russell, Stephen J.; Chadwick, Mark P.; Buchholz, Christian  
PA Cambridge Drug Discovery, Ltd., UK  
SO PCT Int. Appl., 25 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001062972	A1	20010830	WO 2001-US5389	20010220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1282727	A1	20030212	EP 2001-910984	20010220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002009715	A1	20020124	US 2001-791427	20010223
US 6387686	B2	20020514		
PRAI US 2000-184982P	P	20000225		
WO 2001-US5389	W	20010220		
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L7 ANSWER 7 OF 20 WPIDS (C) 2003 THOMSON DERWENT  
AN 2001-582058 [65] WPIDS  
DNC C2001-172577  
TI Identifying polynucleotide encoding protease, comprises packaging target cell RNA into viral display packages that display chimeric or recombinant envelope proteins, and contacting with a second group of target cells.  
DC B04 D16  
IN CHADWICK, M P; RUSSELL, S J  
PA (CAMB-N) CAMBRIDGE DRUG DISCOVERY LTD; (BIOF-N) BIOFOCUS DISCOVERY LTD; (CHAD-I) CHADWICK M P; (RUSS-I) RUSSELL S J  
CYC 95  
PI WO 2001062970 A1 20010830 (200165)\* EN 30p C12Q001-68  
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW  
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
AU 2001047206 A 20010903 (200202) C12Q001-68  
US 2002039729 A1 20020404 (200227) C12Q001-68  
EP 1266036 A1 20021218 (200301) EN C12Q001-68  
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR  
US 6506557 B2 20030114 (200313) C12Q001-70  
ADT WO 2001062970 A1 WO 2001-US5381 20010220; AU 2001047206 A AU 2001-47206 20010220; US 2002039729 A1 Provisional US 2000-184981P 20000225, US 2001-792416 20010223; EP 1266036 A1 EP 2001-920120 20010220, WO 2001-US5381 20010220; US 6506557 B2 Provisional US 2000-184981P 20000225,

US 2001-792416 20010223  
FDT AU 2001047206 A Based on WO 200162970; EP 1266036 A1 Based on WO 200162970  
PRAI US 2000-184981P 20000225; US 2001-792416 20010223  
IC ICM C12Q001-68; C12Q001-70  
ICS C07H021-02; C12N005-00; C12N005-06; C12N007-00; C12N007-01;  
C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74;  
C12P021-06; C12Q001-06; G01N033-53

L7 ANSWER 8 OF 20 MEDLINE DUPLICATE 7  
AN 2001466733 MEDLINE  
DN 21402931 PubMed ID: 11418598  
TI Proteolytic activation of respiratory syncytial virus **fusion**  
protein. **Cleavage** at two **furin** consensus sequences.  
AU Zimmer G; Budz L; Herrler G  
CS Institut für Virologie, Tierärztliche Hochschule Hannover, Bunteweg 17,  
D-30559 Hannover, Germany.  
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (2001 Aug 24) 276 (34) 31642-50.  
Journal code: 2985121R. ISSN: 0021-9258.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200109  
ED Entered STN: 20010821  
Last Updated on STN: 20030105  
Entered Medline: 20010920

L7 ANSWER 9 OF 20 SCISEARCH COPYRIGHT 2003 ISI (R)  
AN 2001:372489 SCISEARCH  
GA The Genuine Article (R) Number: 427CF  
TI Purification and characterization of a Ca<sup>2+</sup>-independent endoprotease  
activity from peripheral blood lymphocytes: Involvement in HIV-1 gp160  
maturation  
AU Bendjennat M; Bahbouhi B; Bahraoui E (Reprint)  
CS Univ Toulouse 3, Lab Immunovirologie, EA 3038, UFR SVT, F-31062 Toulouse,  
France (Reprint)  
CYA France  
SO BIOCHEMISTRY, (17 APR 2001) Vol. 40, No. 15, pp. 4800-4810.  
Publisher: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA.  
ISSN: 0006-2960.  
DT Article; Journal  
LA English  
REC Reference Count: 48  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L7 ANSWER 10 OF 20 MEDLINE DUPLICATE 8  
AN 2000111319 MEDLINE  
DN 20111319 PubMed ID: 10644371  
TI Proteolytic **cleavage** of the **fusion** protein but not  
membrane **fusion** is required for measles virus-induced  
immunosuppression in vitro.  
AU Weidmann A; Maisner A; Garten W; Seufert M; ter Meulen V;  
Schneider-Schaulies S  
CS Institute for Virology and Immunobiology, University of Würzburg, D-97078  
Würzburg, Germany.  
SO JOURNAL OF VIROLOGY, (2000 Feb) 74 (4) 1985-93.  
Journal code: 0113724. ISSN: 0022-538X.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200003  
ED Entered STN: 20000314  
Last Updated on STN: 20000314  
Entered Medline: 20000302

L7 ANSWER 11 OF 20 SCISEARCH COPYRIGHT 2003 ISI (R)  
 AN 2000:766157 SCISEARCH  
 GA The Genuine Article (R) Number: 360ZM  
 TI The **cleavage** activation and sites of glycosylation in the  
**fusion** protein of Hendra virus  
 AU Michalski W P (Reprint); Crameri G; Wang L F; Shiell B J; Eaton B  
 CS CSIRO ANIM HLTH, AUSTRALIAN ANIM HLTH LAB, PRIVATE BAG 24, GEELONG, VIC  
 3220, AUSTRALIA (Reprint)  
 CYA AUSTRALIA  
 SO VIRUS RESEARCH, (25 SEP 2000) Vol. 69, No. 2, pp. 83-93.  
 Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM,  
 NETHERLANDS.  
 ISSN: 0168-1702.  
 DT Article; Journal  
 FS LIFE  
 LA English  
 REC Reference Count: 46  
 \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L7 ANSWER 12 OF 20 MEDLINE DUPLICATE 9  
 AN 2000431780 MEDLINE  
 DN 20390113 PubMed ID: 10930660  
 TI **Cleavage** of the respiratory syncytial virus **fusion**  
 protein is required for its surface expression: role of **furin**.  
 AU Bolt G; Pedersen L O; Birkeslund H H  
 CS Department of Medical Microbiology and Immunology, Panum Institute,  
 University of Copenhagen, Blegdamsvej 3, 2200 N, Copenhagen, Denmark..  
 gb@kvl.dk  
 SO VIRUS RESEARCH, (2000 Jun) 68 (1) 25-33.  
 Journal code: 8410979. ISSN: 0168-1702.  
 CY Netherlands  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200009  
 ED Entered STN: 20000922  
 Last Updated on STN: 20000922  
 Entered Medline: 20000914

L7 ANSWER 13 OF 20 SCISEARCH COPYRIGHT 2003 ISI (R)  
 AN 2000:213418 SCISEARCH  
 GA The Genuine Article (R) Number: 292MA  
 TI Proteolytic processing of Marburg virus glycoprotein  
 AU Volchkov V E (Reprint); Volchkova V A; Stroher U; Becker S; Dolnik O;  
 Cieplik M; Garten W; Klenk H D; Feldmann H  
 CS UNIV MARBURG, INST VIROL, ROBERT KOCH STR 17, D-35037 MARBURG, GERMANY  
 (Reprint)  
 CYA GERMANY  
 SO VIROLOGY, (1 MAR 2000) Vol. 268, No. 1, pp. 1-6.  
 Publisher: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA  
 92101-4495.  
 ISSN: 0042-6822.  
 DT Article; Journal  
 FS LIFE  
 LA English  
 REC Reference Count: 46  
 \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L7 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2003 ACS  
 AN 1999:795994 HCAPLUS  
 DN 132:31744  
 TI Gene probes used for genetic profiling in healthcare screening and  
 planning  
 IN Roberts, Gareth Wyn  
 PA Genostic Pharma Ltd., UK  
 SO PCT Int. Appl., 745 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English



FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9964627	A2	19991216	WO 1999-GB1780	19990604
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	GB 1998-12099	A	19980606		
	GB 1998-13291	A	19980620		
	GB 1998-13611	A	19980624		
	GB 1998-13835	A	19980627		
	GB 1998-14110	A	19980701		
	GB 1998-14580	A	19980707		
	GB 1998-15438	A	19980716		
	GB 1998-15574	A	19980718		
	GB 1998-15576	A	19980718		
	GB 1998-16085	A	19980724		
	GB 1998-16086	A	19980724		
	GB 1998-16921	A	19980805		
	GB 1998-17097	A	19980807		
	GB 1998-17200	A	19980808		
	GB 1998-17632	A	19980814		
	GB 1998-17943	A	19980819		

L7 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2003 ACS  
AN 1999:795993 HCAPLUS  
DN 132:31743  
TI Gene probes used for genetic profiling in healthcare screening and planning  
IN Roberts, Gareth Wyn  
PA Genostic Pharma Limited, UK  
SO PCT Int. Appl., 149 pp.  
CODEN: PIXXD2  
DT Patent  
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9964626	A2	19991216	WO 1999-GB1779	19990604
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2330929	AA	19991216	CA 1999-2330929	19990604
	AU 9941586	A1	19991230	AU 1999-41586	19990604
	AU 9941587	A1	19991230	AU 1999-41587	19990604
	GB 2339200	A1	20000119	GB 1999-12914	19990604
	GB 2339200	B2	20010912		
	EP 1084273	A1	20010321	EP 1999-925207	19990604
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	GB 1998-12098	A	19980606		
	GB 1998-28289	A	19981223		
	GB 1998-16086	A	19980724		
	GB 1998-16921	A	19980805		
	GB 1998-17097	A	19980807		
	GB 1998-17200	A	19980808		
	GB 1998-17632	A	19980814		

GB 1998-17943 A 19980609  
WO 1999-GB1779 W 19990604

L7 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2003 ACS  
AN 1999:753357 HCAPLUS  
DN 132:9591  
TI Polyproteins **cleavable** by ubiquitous endoproteases to release  
several constituent therapeutic proteins and expression constructs for use  
in gene therapy  
IN Gaken, Johannes Adrianus; Farzaneh, Farzin; Russell, Stephen James  
PA UK  
SO PCT Int. Appl., 44 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9960135	A1	19991125	WO 1999-GB1609	19990521
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2333144	AA	19991125	CA 1999-2333144	19990521
	AU 9940508	A1	19991206	AU 1999-40508	19990521
	AU 753785	B2	20021031		
	EP 1080206	A1	20010307	EP 1999-923745	19990521
	EP 1080206	B1	20030402		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002515251	T2	20020528	JP 2000-549741	19990521
PRAI	GB 1998-10999	A	19980521		
	WO 1999-GB1609	W	19990521		
OS	MARPAT 132:9591				
RE.CNT	11	THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L7 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2003 ACS  
AN 1999:673041 HCAPLUS  
DN 131:282025  
TI Improved methods for making hormone heterodimers for therapeutic and  
disagnostic purposes  
IN Moyle, William R.  
PA University of Medicine & Dentistry of New Jersey, USA  
SO PCT Int. Appl., 73 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9953065	A1	19991021	WO 1999-US8018	19990413
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6486303	B1	20021126	US 1998-59625	19980414
	AU 9935561	A1	19991101	AU 1999-35561	19990413
PRAI	US 1998-59625	A	19980414		
	WO 1999-US8018	W	19990413		
RE.CNT	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L7 ANSWER 18 OF 20 MEDLINE  
AN 1999185011 MEDLINE

DN 99185011 PubMed ID: 10085  
TI Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells.  
AU Singh Y; Klimpel K R; Goel S; Swain P K; Leppla S H  
CS Centre for Biochemical Technology, Delhi 110007, India.  
SO INFECTION AND IMMUNITY, (1999 Apr) 67 (4) 1853-9.  
Journal code: 0246127. ISSN: 0019-9567.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199904  
ED Entered STN: 19990511  
Last Updated on STN: 19990511  
Entered Medline: 19990426

L7 ANSWER 19 OF 20 SCISEARCH COPYRIGHT 2003 ISI (R)  
AN 1999:617619 SCISEARCH  
GA The Genuine Article (R) Number: 223DP  
TI The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis  
AU Feldmann H; Volchkov V E; Volchkova V A; Klenk H D (Reprint)  
CS UNIV MARBURG, INST VIROL, POSTFACH 2360, D-35011 MARBURG, GERMANY (Reprint); UNIV MARBURG, INST VIROL, D-35011 MARBURG, GERMANY  
CYA GERMANY  
SO ARCHIVES OF VIROLOGY, (AUG 1999) Supp. [15], pp. 159-169.  
Publisher: SPRINGER-VERLAG WIEN, SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA.  
ISSN: 0304-8608.  
DT Article; Journal  
FS LIFE  
LA English  
REC Reference Count: 53  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L7 ANSWER 20 OF 20 MEDLINE DUPLICATE 10  
AN 1999097444 MEDLINE  
DN 99097444 PubMed ID: 9878618  
TI The role of subtilisin-like proprotein convertases for cleavage of the measles virus fusion glycoprotein in different cell types.  
AU Bolt G; Pedersen I R  
CS Panum Institute, University of Copenhagen, Blegdamsvej 3, Copenhagen N, 2200, Denmark.. G.Bolt@immi.ku.dk  
SO VIROLOGY, (1998 Dec 20) 252 (2) 387-98.  
Journal code: 0110674. ISSN: 0042-6822.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199901  
ED Entered STN: 19990209  
Last Updated on STN: 20000303  
Entered Medline: 19990128

=> dis his

(FILE 'HOME' ENTERED AT 16:12:18 ON 17 APR 2003)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIODBASE, BIOTECHNO, WPIDS' ENTERED AT 16:14:55 ON 17 APR 2003

L1 206 S FURIN AND REVIEW  
L2 2109 S FURIN/TI  
L3 8 S L1 AND SUBUNIT  
L4 5 DUP REM L3 (3 DUPLICATES REMOVED)  
L5 96 S FURIN AND SUBUNIT AND FUSION  
L6 82 S L5 AND CLEAV?  
L7 20 DUP REM L6 (62 DUPLICATES REMOVED)

=> log h